The study, published in Clinical Cancer Research, confirms that the Endocrine Activity Index (EAI) can distinguish which patients respond to taxane-based chemotherapy. Researchers from the GEICAM Spanish Breast Cancer Group and MD Anderson Cancer Center examined tumor samples from a phase III trial, finding that individuals with an EAI score below 0.75 experienced improved distant recurrence-free outcomes when weekly paclitaxel was added to their treatment. Conversely, patients with higher endocrine activity levels saw no additional benefit from the regimen.
Delphi Diagnostics Genomic Test Predicts Paclitaxel Benefit in Breast Cancer
Patients with HR+/HER2− breast cancer showing low endocrine activity derive significant clinical benefit from weekly paclitaxel, according to a new analysis of the GEICAM/9906 trial. The findings establish Delphi Diagnostics’ Endocrine Activity Index as a predictive tool for tailoring chemotherapy regimens beyond standard recurrence risk assessments.
Approximately 16% of the HR+/HER2− tumors analyzed demonstrated this low endocrine activity profile. Federico A. Monzon, Chief Medical Officer at Delphi Diagnostics, noted that the data provides independent validation for using biological markers to personalize oncology care. Unlike traditional assays that primarily estimate overall recurrence risk, this genomic approach identifies specific drug sensitivities, potentially sparing patients from unnecessary exposure to ineffective treatments.
Comments (0)
No comments yet. Be the first!